GSK is frequently cited as a top "value stock" for income seekers, offering a healthy 3.27% - 3.4% dividend yield . The company expects to raise its 2026 dividend to 70p. The "Sell" or "Hold" Case: Technical & Near-Term Pressure
Management has reaffirmed its 2026 outlook, expecting core EPS growth of 7% to 9%. Key growth drivers include Arexvy (RSV vaccine) and expansion into specialty medicines like HIV and Oncology. gsk buy or sell
As of late April 2026, the consensus among financial analysts for leans toward a Hold , though it remains a polarizing "value" play with significant long-term upside potential. The "Buy" Case: Long-Term Growth & Valuation GSK is frequently cited as a top "value
For investors with a longer time horizon, GSK presents a compelling "Buy" narrative centered on its successful pivot to a high-margin, pure-play pharmaceutical company: Key growth drivers include Arexvy (RSV vaccine) and
Several valuation models suggest the stock is significantly undervalued. Discounted Cash Flow (DCF) analyses from Yahoo Finance estimate the stock is trading at a ~52-53% discount to its fair value.
Despite strong fundamentals, many analysts recommend caution in the immediate term: GSK (GSK) Earnings Expected to Grow: Should You Buy?